FDA MONITORING OF PHARMACOECONOMIC DATA SHOULD BE LIMITED TO "EGREGIOUS" MATERIAL, PhRMA SAYS; MFRS. ARGUE FOR FLEXIBLE SUBSTANTIATION OF P-E CLAIMS
Executive Summary
Citing its legislative proposal for FDA reform, the Pharmaceutical Research & Manufacturers of America suggests that the agency's role in monitoring the dissemination of pharmacoeconomic information should be restricted to preventing the spread of "egregious promotional material."